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AbsTrACT
Objective To analyse predictors for relapses and 
number of attacks under different immunotherapies in 
patients with neuromyelitis optica spectrum disorder 
(NMOsD).
Design This is a retrospective cohort study conducted 
in neurology departments at 21 regional and 
university hospitals in Germany. eligible participants 
were patients with aquaporin-4-antibody-positive 
or aquaporin-4-antibody-negative NMOsD. Main 
outcome measures were hRs from cox proportional 
hazard regression models adjusted for centre effects, 
important prognostic factors and repeated treatment 
episodes.
results 265 treatment episodes with a mean 
duration of 442 days (total of 321 treatment years) 
in 144 patients (mean age at first attack: 40.9 years, 
82.6% female, 86.1% aquaporin-4-antibody-positive) 
were analysed. 191 attacks occurred during any of 
the treatments (annual relapse rate=0.60). The most 
common treatments were rituximab (n=77, 111 
patient-years), azathioprine (n=52, 68 patient-years), 
interferon-β (n=32, 61 patient-years), mitoxantrone 
(n=34, 32.1 patient-years) and glatiramer acetate 
(n=17, 10 patient-years). azathioprine (hR=0.4, 
95% cI 0.3 to 0.7, p=0.001) and rituximab (hR=0.6, 
95% cI 0.4 to 1.0, p=0.034) reduced the attack risk 
compared with interferon-β, whereas mitoxantrone 
and glatiramer acetate did not. patients who were 
aquaporin-4-antibody-positive had a higher risk of 
attacks (hR=2.5, 95% cI 1.3 to 5.1, p=0.009). every 
decade of age was associated with a lower risk for 
attacks (hR=0.8, 95% cI 0.7 to 1.0, p=0.039). a 
previous attack under the same treatment tended to 
be predictive for further attacks (hR=1.5, 95% cI 1.0 
to 2.4, p=0.065).
Conclusions age, antibody status and possibly 
previous attacks predict further attacks in patients 
treated for NMOsD. azathioprine and rituximab are 
superior to interferon-β.
INTrODuCTION
Neuromyelitis optica spectrum disorder (NMOSD) 
is a rare autoimmune disease of the central nervous 
system, mainly manifesting through recurrent attacks 
of optic neuritis and longitudinally extensive trans-
verse myelitis.1 Antibodies to aquaporin-4 (AQP4-abs) 
were identified as pathogenic, and their detection, in 
addition to typical clinical manifestation, is a hall-
mark of the recently updated diagnostic criteria.2–4 
The presence of AQP4-abs is also related to prognosis 
and attack risk.5 6 While a chronic progressive disease 
course is very rare, inflammatory disease attacks are 
associated with a high risk of persisting disability, 
including paraplegia and blindness.7 8 Attack preven-
tion with immunosuppressive drugs is currently 
considered the best available treatment.9–11 Besides 
classical immunosuppressant drugs such as azathi-
oprine (AZA) or mycophenolate mofetil (MMF), 
rituximab (RTX) has increasingly been used for the 
treatment of patients with NMOSD since 2005.12–17 
More recently, an interleukin-6 receptor inhibitor 
(SA-237), eculizumab and an anti-CD19 antibody 
(inebilizumab) are being investigated as alternative 
therapies.18–21 However, currently only low evidence 
exists concerning comparative treatment efficacy. 
The best available data so far, generated in a retro-
spective analysis of 90 patients with NMOSD from 
the USA22 and of 138 patients with NMOSD from 
Korea,23 describe greater efficacy of RTX and MMF 
compared with AZA. Furthermore, little is known 
about predictors for treatment response,24 and it is 
unknown whether AQP4-ab serostatus, gender, age, 
disease duration and other clinical parameters are 
associated with attack-free survival under treatment. 
As long as large prospective cohorts or randomised 
trials, which are difficult to perform due to the rarity 
of NMOSD, are lacking, retrospective cohort studies 
are the best available approach to gain further knowl-
edge about treatment efficacy and predictors of treat-
ment response. Using the NMOSD registry of the 
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German Neuromyelitis Optica Study group (NEMOS), we anal-
ysed the efficacy of immunotherapies for attack prevention and 
predictors for attacks under immunotherapies.
MeThODs
study design and patients
This retrospective cohort study was based on the German 
NEMOS group (www. nemos- net. de) registry established in 
2008. At database lock, the registry included 186 patients with 
neuromyelitis optica (NMO) diagnosed according to the 2006 
Wingerchuk25 criteria or with AQP4-ab-positive NMO spectrum 
disorder (NMOSD). The local institutional review boards of the 
participating centres approved the study (first approval from the 
institutional review board Charité Universitätsmedizin Berlin 
EA3/004/08). Last data entry for this analysis varied between 
centres and was between January 2012 and March 2013.
Data collection and processing
Data collected at regular clinical visits included demographic 
data, AQP4-ab status, attacks (onset, treatments and outcome), 
long-term treatments (compounds, start/stop dates and dosages), 
expanded disability status scale and visual acuity. A detailed 
description of the cohort and the methods used for data collec-
tion, including an on-site data validation (‘flying doctor-ap-
proach’), has been published previously.8
For this study, demographic data, long-term treatment data 
and attack dates were extracted from the database. Treatment 
data were validated through manual quality checks performed 
by two authors (JPS and MK), as well as by automated logical 
checks. As further analyses relied on exact treatment data, 
including start and stop dates, patients with insufficient baseline 
or treatment data were excluded.
Definition of treatment episodes
For our analyses which were based on pharmacodynamics and 
previous treatment experience, we determined the efficacy of 
therapeutic interventions after the last dose as follows: 365 days 
for alemtuzumab; 180 days for RTX; 90 days for mitoxantrone 
(Mitox) and intrathecal steroids; 30 days for cyclophosphamide, 
AZA, ciclosporin A, MMF, natalizumab, intravenous immu-
noglobulin, fingolimod (FTY), intravenous steroids and tocili-
zumab (TCZ); and 7 days for interferon-β (IFN), glatiramer 
acetate (GLAT), methotrexate and oral steroids. Treatment 
duration was prolonged if the documented stop date (ie, clin-
ical decision to not further proceed with the current treatment) 
was before the end of effectiveness as defined above. In recur-
rent treatment episodes with the same compound (observed for 
AZA, RTX, Mitox and IFN), we merged the two cycles if the 
first dose of the second episode was administered less than 30 
days (AZA, RTX, Mitox) or 10 days (IFN) after the assumed 
end of effectiveness, for example two RTX cycles 200 days 
apart were considered as one continuous treatment episode. 
For other treatments, no recurrent treatment episodes were 
observed. Gaps longer than the mentioned period were treated 
as separated episodes in further analyses. Treatments with uncer-
tain treatment start or stop dates were excluded. Finally, in 59 
treatments an overlap of treatment durations as defined by the 
above-mentioned effectiveness time or a combination of two 
or three compounds occurred (online supplementary table 1). 
Unfortunately, these groups were too small and too heteroge-
neous to reliably investigate combination therapies. Therefore, 
our analyses were restricted to monotherapies.
Data sets
Two data sets were defined. Data set A included all available 
treatment data for descriptive statistics, its changes over time 
and for computing unadjusted annual relapse rates (ARR).
In Data set B, recurrent event analyses considering the time 
from treatment start to attack were performed. Treatment 
episodes from patients with an attack under the treatment were 
split in separate episodes by the date of attack onset. Each treat-
ment episode was labelled as stable if no attack occurred and as 
failure if an attack occurred. Treatment episodes shorter than 
14 days or with unreliable start and stop dates were excluded. 
For efficacy analyses and response predictors, we reduced the 
data set to compounds with at least 10 patient-years in at least 
10 patients (Data set B).
statistical analyses
Our statistical analysis plan was designed (1) to investigate 
prescription reality of immunotherapies in Germany and their 
changes over time, (2) to compare efficacy of treatments in 
recurrent event analyses and (3) to explore the data set for 
predictors of relapses.
Using Data set A, descriptive statistics of the cohort were 
performed. To investigate if prescription routine changed over 
time, the χ2 test was used to compare frequencies before and 
after publication of the German NMO treatment guidelines 
by NEMOS in early 2011.26 Under the assumption that attack 
occurrence follows a Poisson distribution, we estimated annu-
alised relapse rates (ARR, mean number of relapses per treat-
ment year) and 95% CIs. ARR estimates were unadjusted for any 
covariates. Differences between the cohorts were tested with χ2 
test (rates) or analysis of variance (continuous data).
For the analysis of Data set B, the multivariate cox proportional 
hazard regression models for recurrent events were computed.27 
We aimed to compare treatment effects and to investigate the 
influence of potential predictors of attack risk: age, gender, 
previous attack under therapy, line of treatment for the indi-
vidual patient (labelled as first line, second line, or third or more 
line), AQP4-ab status and whether the 2006 Wingerchuk criteria 
were fulfilled. The patient ID was included as cluster variable to 
account for intraindividual correlation of observations, and the 
models were additionally corrected for centre effects. In a first 
step, a multivariate model was performed, including predictors 
and treatments, and HRs and their 95% CIs were computed. 
Second, the number of variables in the model was reduced by 
excluding all variables not showing at least a trend towards 
significance (defined as p<0.1). As no untreated or placebo 
cohort for estimating HRs was available, IFN was chosen as a 
reference category for all treatment comparisons, as IFN was 
shown to be without clinical efficacy in NMOSD.28 To compare 
predictors between different treatments, we performed post-hoc 
analyses for each treatment subgroup. p Values <0.05 were 
considered statistically significant. All analyses were performed 
with Statistics in R (V.3.2.3), including the survival package.29
resulTs
Description of the cohort
One hundred and eighty-six patients with NMO or AQP4-ab-pos-
itive NMOSD were documented in the NEMOS registry. After 
exclusion of incomplete and uncertain treatment data as well as 
overlapping treatments, 265 different treatments in 144 patients 
from 21 centres could be extracted (figure 1). The majority of 
patients were female (n=119, 82.6%), fulfilled the 2006 Wing-
erchuk diagnostic criteria (n=113, 78.5%) and were seropositive 
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for AQP4-ab (n=124, 86.1%). The mean age at disease onset was 
40.9 (SD: 14.3) years and the median follow-up time was 6.1 
(0.1–34.9) years. The median number of immunotherapies per 
patient was 2 (1–8). The mean duration of treatments was 442 
(SD: 432) days, summing up to a total of 321 documented treat-
ment years. One hundred and thirty-seven treatments were given 
as first-line therapy in the individual patient, 69 as second-line 
and 59 as third-line (or more). One hundred and ninety-one 
attacks occurred during the documented treatments, resulting in 
an overall ARR of 0.60 (95% CI 0.51 to 0.69) in treated patients.
Frequencies, prescription changes and unadjusted attack 
rates for all treatments
We identified 15 different immunotherapy drugs, which were 
used in 1–65 (median: 7) patients (table 1). The most commonly 
used compounds were RTX, with 111 patient years in 65 patients, 
AZA with 68 patient-years in 46 patients and IFN with 61 patient-
years in 30 patients. The mean treatment duration ranged from 
77 (FTY) to 699 (IFN) days. Unadjusted ARRs and 95% CI of 
all treatments are presented in table 1. The prescription of 
compounds changed over time. Of the most commonly prescribed 
drugs, RTX (first given in 2005) showed an increase from 24% to 
43% of all prescriptions with the cut-off of 2011, whereas Mitox 
use decreased from 16% to 2% and IFN treatment was not further 
initiated after 2011. The use of all medications over time and of 
all relapses occurring during treatment are visualised in figure 2.
Detailed dosing data for these treatments were available in 
most cases (AZA: 94%, GLAT: 78%, IFN: 88%, Mitox: 87%, 
RTX: 98%). GLAT patients received 20 mg/day, 69% of IFN 
treatments used the full dose and 31% a reduced dose (eight 
times IFN-β-1-a subcutaneous 22 µg, one time IFN-β-1-a intra-
muscular 8 mg). The median dose of Mitox was 12 mg/m2 body 
surface (range: 10–12 mg) every 3 months. The median dose of 
AZA was 150 mg per day (mean: 126 mg, range: 50–300 mg). 
Fifty per cent of AZA doses were 150 mg or above and 82% at 
least 100 mg/day. However, sufficiency of AZA dosing could not 
be reliably evaluated, as body weight data were not available. 
The median dose of 1000 mg per cycle (one or two infusions) 
of RTX (range: 375–3000 mg) or more was applied in 79% of 
treatments, usually every 6 months.
Figure 1 Flow chart of data processing and exclusions. Data set a used for descriptive statistics. Data set B included in recurrent event analyses 
considering the time to the next attack. For details, see the Methods section. NeMOs, Neuromyelitis Optica study group.
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The compounds AZA, IFN and RTX were the most often used 
first-line therapies in our cohort. RTX was the most often used 
second-line or third-line therapy. The sequence of compounds 
used was very heterogeneous, and we did not observe any 
obvious pattern of typical therapy sequences.
Analysis of predictors of attack risk
Five treatments (AZA, GLAT, IFN, Mitox and RTX) had at 
least 10 patient-years in at least 10 patients. Three hundred 
and twenty-two treatment episodes from 127 patients (20 
centres) labelled as ‘stable’ (n=191, 59%) or ‘failure’ (n=131, 
41%) were included in these analyses. The observation time in 
this data set included a total of 261.7 patient-years. The five 
treatment cohorts did not differ significantly concerning gender, 
proportion of patients positive for AQP4-ab or meeting the 
2006 Wingerchuk criteria,25 respectively (table 2).
The analysis for independent treatment response predictors 
revealed that AQP4-ab-positive patients had a higher risk of 
attacks than AQP4-ab-negative patients (HR=2.54, 95% CI 1.26 
to 5.12, p=0.009). A previous attack under the same treatment 
tended to increase the risk of a subsequent attack (HR=1.53, 
95% CI 0.97 to 2.42, p=0.065). In contrast, every added decade 
of age was associated with a lower attack risk (HR=0.82, 95% CI 
0.69 to 0.99, p=0.039). Other variables were not significantly 
associated with attack risk (figure 3). Post-hoc, we analysed 
if predictors differed between the treatments. However, due 
Figure 2 Treatments in the Neuromyelitis Optica study group cohort. Lines represent all treatment episodes over time. attacks are marked as black 
diamonds. Data are sorted by compounds. aZa, azathioprine; csa, ciclosporin a; cYc, cyclophosphamide; FTY, fingolimod; GLaT, glatiramer acetate; 
IFN, interferon-β; IVIg, intravenous immunoglobulins; Mitox, mitoxantrone; MMF, mycophenolate mofetil; MTX, methotrexate; NaT, natalizumab; 
RTX, rituximab; i.th., intrathecal; p.o., per os; TcZ, tocilizumab.
Table 2 Descriptive statistics of groups used for survival analyses (data set B)
AZA GlAT IFN Mitox rTX p Value
Treatments
  Patient-years, sum  63.3 10.3 61.2 30.5 96.2
  Episodes, n (%)  67 (20.8) 28 (8.7) 74 (23) 48 (14.9) 105 (32.6) <0.001
  Attack-free episodes, n (%)  47 (70.1) 16 (57.1) 30 (40.5) 30 (62.5) 68 (64.8)  0.07
  No previous attack under same therapy, n (%)  49 (73.1) 17 (60.7) 30 (40.5) 32 (66.7) 70 (66.7)  0.001
  First-line therapy, n (%)  41 (24.7) 14 (8.4) 60 (36.1) 25 (15.1) 26 (16.0) <0.001
  Dose, mean (SD) 128 (44.5) mg/day 20 mg/day Various
11.4 (1.0) mg/
m2 body surface 963 (337) mg/cycle NA
  Dose, median (range)
150 (12.5–300) mg/
day 20 mg/day Various
12 (10–12) mg/m2  
body surface
1000 (375–3000) mg/
cycle NA
Patients
  Patients receiving treatment, n (%)  45 (24.2) 17 (9.1) 30 (16.1) 32 (17.2) 62 (33.3)  0.002
  Age at start, mean (SD), years  39.2 (13.3) 34.1 (11.5) 31.8 (11.9) 43.5 (14.5) 44.1 (14.6) <0.001
  Females, n (%)  41 (91.1) 16 (94.1) 25 (83.3) 24 (75.0) 51 (82.3)  0.6
  2006 Wingerchuk criteria fulfilled, n (%)  33 (73.3) 14 (82.4) 29 (96.7) 25 (78.1) 48 (77.4)  0.4
  AQP4-ab-positive, n (%)  39 (86.7) 11 (64.7) 27 (90.0) 28 (87.5) 54 (87.1)  0.3
Differences between groups tested with χ2 test for rates or analysis of variance for continuous measures.
AQP4-ab, antibodies against aquaporin-4; AZA, azathioprine; GLAT, glatiramer acetate; IFN, interferon-β; Mitox, mitoxantrone; NA, not applicable; RTX, rituximab.
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to the low patient numbers and the lack of events in certain 
subgroups, we could not reliably estimate HR in every case. For 
AZA and IFN, neither age, disease duration, previous attacks 
nor AQP4-abs were predictive for attacks. In contrast, patients 
treated with RTX had a higher risk for attacks if they were posi-
tive for AQP4-abs (HR estimate unreliable, p<0.001). The attack 
risk under Mitox decreased with every decade of age (HR=0.54, 
95% CI 0.35 to 0.85) and was increased after a previous attack 
under Mitox (HR=2.84, 95% CI 1.17 to 6.88). Decades of age 
(HR=0.54, 95% CI: 0.37 to 0.79, p<0.001) and disease dura-
tion (HR=0.04, 95% CI 0.01 to 0.30) were predictive for fewer 
attacks under GLAT, while the presence of AQP4-ab was associ-
ated with higher attack risk (HR estimate unreliable, p<0.001).
Adjusted for AQP4-ab status, age, disease duration and any 
previous attacks under a therapy, only AZA (HR=0.43, 95% CI 
0.26 to 0.71, p=0.001) and RTX (HR=0.60, 95% CI 0.38 to 
0.96, p=0.034) reduced the attack risk compared with IFN 
therapy (figure 3). No statistically significant differences were 
found between IFN and GLAT or Mitox.
As only AZA and RTX were superior to IFN, we added 
explorative analyses to elucidate if subgroups of patients might 
have a more pronounced benefit from either treatment. Within 
models of direct comparison, neither the use as a first-line nor 
as second-line/third-line treatment revealed differences between 
the two drugs. A previous treatment failure under AZA did not 
predict a better treatment response under RTX when compared 
with the AZA period in the same patient; however, only 10 
patients were available for this analysis. A comparison vice versa 
was not possible as only three patients were switched from RTX 
to AZA. Due to the shift towards more RTX prescriptions, the 
influence of the year of treatment start was additionally tested, 
but a significant influence was not detected.
DIsCussION
Patients with NMOSD should receive immunotherapy as early 
as possible, as any further attack may cause serious and often 
irreversible disability.10 11 30 However, current knowledge 
about sequences of immunotherapies, predictors for therapy 
response or comparison between treatments is limited. The 
NEMOS database allowed us to analyse ‘real life’ management 
of NMOSD in a large cohort of 144 patients with NMOSD and 
an observation period of 321 treatment years.
Patients were cared for at 16 tertiary centres and 5 regional 
hospitals, therefore covering a study population representative 
for German patients with NMOSD and the diversity of care. 
Fifteen different immunotherapeutic drugs were used for the 
treatment of NMOSD, indicating a heterogeneous treatment 
of our cohort. The most commonly used drugs were RTX, 
AZA, IFN, Mitox and GLAT. The high prevalence of drugs 
regularly used for mulitple sclerosis (MS) and now abandoned 
for NMOSD probably is due to initial misdiagnosis of patients 
before AQP4-ab testing has become widely available and the fact 
that inefficacy of these drugs for NMOSD was unknown at that 
time. As the data closure of this study was already in 2013, data 
on longer use of RTX and on some of the recently emerging 
therapies such as TCZ are limited.
Overall, we found moderate to low unadjusted ARRs under 
RTX and AZA, the two most commonly used drugs for NMOSD 
in our cohort. This is in line with other studies reporting ARRs 
under these therapies of between 0.1 and 0.9.6 12 14 15 17 24 31–33
The proportion of patients treated with drugs regularly used 
for MS therapy declined over the observation period and RTX 
gained share, in line with its introduction as first-line recommen-
dation for NMOSD in Germany.26 Of note, while initiation of a 
drug is guided by recommendations, staying on a drug is influ-
enced by the absence of disease activity and adverse effects. The 
relative gain of RTX over AZA since 2011 might also be related 
to its better tolerability.
Using a multivariable model, we compared the effect on 
disease activity of different immunotherapies. RTX and AZA 
were the only two drugs that had significantly lower attack rates 
than IFN. GLAT and Mitox were not superior to IFN. IFN with 
its known lacking efficacy28 34 35 was used as reference as the 
percentage of untreated patients was too small. The design of 
our study was not suitable for a direct comparison between AZA 
and RTX. The appearance of potential similar efficacy should 
therefore be interpreted with caution and currently cannot be 
translated into treatment recommendations.
Figure 3 hRs for predictors and treatments. hR and 95% cIs for clinical predictors of treatment response and different treatments (interferon-β as 
reference). age and disease duration as decades. Variables not included in the final model: line of therapy, gender and whether the 2006 Wingerchuk 
criteria were fulfilled. For details, see the Methods section. aQp4-ab, antibodies against aquaporin-4; aZa, azathioprine; GLaT, glatiramer acetate; 
Mitox, mitoxantrone; RTX, rituximab. *Represent statistically significant data.
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Two previous studies had indeed suggested superiority of 
RTX over AZA.22 23 While our study included mainly Caucasian 
patients, these two other retrospective cohorts included African 
or predominantly Asian patients.22 23 Genetic differences have 
been previously suggested to contribute to the RTX therapy 
response in NMOSD.17 Moreover, previous studies had excluded 
patients with a history of previous immunosuppressive treat-
ment. By contrast, such patients were included in our analyses, 
which is in line with the fact that most patients with NMOSD are 
treated with more than one immunosuppressant over the course 
of disease.5 23 In our cohort, RTX was used in >60% as second-
line therapy or even later. Treatment was changed from AZA to 
RTX in eight patients. This could have generated a bias in favour 
of a low ARR in the AZA subgroup, as patients who responded 
well to the treatment might have remained on therapy more 
often as reported in another cohort;31 in addition, patients with 
a high ARR under AZA treatment might have been switched to 
RTX. Moreover, we cannot completely exclude that patients 
with more aggressive disease were more commonly treated with 
RTX than AZA based on the presumption of treatment superi-
ority.
Our study identified predictors for therapy response indepen-
dent from the chosen compound. First, the presence of AQP4-ab 
was identified as risk factor for attacks under therapy. Post-hoc 
analyses suggest that this aspect might be more important in 
RTX-treated than in AZA-treated patients. This is in line with a 
previous study that did not detect an association between attack 
risk and AQP-4-ab in AZA-treated and MMF-treated patients, 
but described a decrease of attack risk with age.36 However, the 
sample sizes are too small to draw final conclusions from our 
explorative analysis. Second, we found that a previous attack 
under the same therapy was associated with a 1.5-fold increased 
risk for further attacks. Therefore, any attack under a sufficiently 
dosed therapy should stipulate a discussion about alternative 
treatment regimes, even if the current knowledge about esca-
lation regimes forbids a strict ‘attack equals treatment change’ 
algorithm. As treatment response in our cohort was completely 
independent from the line of therapy, suggestions on partic-
ular escalation regimes cannot be inferred. Recently, Kim et al 
reported in a retrospective study of 116 patients with NMOSD 
that non-responders to first-line therapy with AZA or MMF had 
less relapses on subsequent therapy with RTX.36 However, still 
larger and longer observations are needed to provide data on 
meaningful sequences of therapies. The higher risk of attacks in 
AQP4-ab-positive patients is in line with previous observations 
in untreated patients5 37 and indicates that these patients are 
facing higher inflammatory and more aggressive disease courses 
than AQP4-ab-negative patients with an NMOSD phenotype. 
Third, we found a decreased attack risk with increasing age. 
This suggests that the shorter time to disability milestones in 
elderly reported in the literature38 is rather driven by worse 
attack outcome than by higher attack rates. In accordance with 
this hypothesis, we found a lower remission rate with increasing 
age in the NEMOS cohort in our previous study.8
Using a retrospective data set, our study has several limitations. 
As patients with NMOSD generally require immunotherapy, we 
could not compare treated and untreated patients; therefore, we 
used the probably worst performing compound (IFN) as a refer-
ence. Second, pretreatment data could not be reliably assessed, 
which impeded comparison between attack risks before and 
during first-line treatment of NMOSD. Moreover, we cannot 
exclude that assignment to drugs regularly used for MS therapy 
might have been influenced by milder diseases courses. Third, as 
detailed drug dosing information was not available in all patients, 
treatment effects could have been underestimated or overesti-
mated. Due to the restricted sample size, we were not able to 
provide differentiated efficacy estimates for all treatments or 
subgroup of patients. Finally, as the severity of relapses was not 
evaluated, differences in efficacy among the drugs could only be 
assessed with regard to relapse frequency. In future prospective 
studies, severity of relapses should be recorded.
Although we tried to compensate for other (in this regard 
confounding) factors when analysing HRs for each therapeutic 
compound, only randomised, blinded clinical trials can provide 
highest level evidence for therapy guidelines. However, this 
is difficult with NMOSD being a rare disease, and thus retro-
spective analyses of registry data are the currently best avail-
able option. Moreover, given the paucity of patients eligible for 
such prospective interventional clinical trials, it is of paramount 
importance to sharpen hypotheses to test in such trials using all 
retrospective data available. National and international collabo-
rative initiatives are needed to engage towards prospective data 
collection as currently realised for the NEMOS cohort.
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